Please login to the form below

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Roche pulls EU Tecentriq/Avastin filing in kidney cancer

inhibitor Keytruda (pembrolizumab) from Merck &Co/MSD, including impressive survival data in combination with Pfizer’s Inlyta (axitinib) in the phase 3 KEYNOTE-426 trial reported at this year’s ESMO

Latest news

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

inhibitor Bavencio (avelumab) – both given in tandem with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib) – leading to them being touted as a potential new treatment standard for these patients.
Merck’s Bavencio joins first-line kidney cancer face-off

The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a ... Combine that with the positive data reported
Keytruda hits survival targets in first-line kidney cancer

Pfizer’s VEGF-targeting Inlyta (axitinib), showing that the duo improved overall survival (OS) and progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib). ... Pfizer when it presents the JAVELIN Renal 101 study of its PD-1 drug
A look ahead to key trial readouts at ESMO

101 study, the first time that a checkpoint inhibitor has shown an increase in progression-free survival (PFS) when combined with a tyrosine kinase inhibitor – in this case Pfizer’s Inlyta
Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Pfizer’s hopes of reversing the decline of its renal cell carcinoma (RCC) treatment Inlyta have taken a knock with a failed phase III trial in patients with less advanced disease. ... The ATLAS study was testing whether VEGF inhibitor Inlyta (axitinib)

More from news
Approximately 7 fully matching, plus 28 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The therapy area is dominated by Merck’s Keytruda, BMS’Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously
Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

A stumble, but not a fall – what’s next for Opdivo?

Back then, the UK’ s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
Oncology drugs under AMNOG

A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Medical/ Scientific Director: Salary TBC

Associate Director: £75, 000-90, 000

Senior Account Executive, London, Medical Communications: Excellent package

Production Manager – Healthcare Communications: DOE

Associate Editorial Director – Med Comms – London: Salary TBC

Scientific Director / Editorial Team Leader: Great salary and benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Medical Writer: Great salary and benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Medical Writers: Competitive Salary and Benefits

Client Services Director – Medical Education Agency – North West...: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Director, Market Access / HEOR - North-West: Negotiable

Associate Director, Market Access & HEOR – North-West: Negotiable

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Consultant Health Economics - London / Oxford: Negotiable

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Medical Writers Required – Cheshire: DOE

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...